Navigation Links
NITTO DENKO Avecia Inc. Introduces Dedicated Pre-Clinical Oligonucleotide Service, OliGrow
Date:5/13/2013

Milford, Massachusetts (PRWEB) May 13, 2013

NITTO DENKO Avecia Inc., an industry leader in therapeutic nucleic acid manufacturing and development services, is proud to introduce a new pre-clinical oligonucleotide synthesis service, OliGrow. Combining phase appropriate quality and purity standards with a high level of customer service, the Avecia OliGrow team delivers pre-clinical oligonucleotides at µmol to mmol scales, with affordable pricing and fast turn around times.

OliGrow offers custom DNA and RNA with standard chemical modifications, along with advanced solutions for more specialized needs, including oligonucleotide conjugates and specialty amidites. Its experts operate within a dedicated facility at Avecia’s FDA- registered Cincinnati, OH plant, and use instrumentation, methods, and analytics designed for scalability and consistency throughout the development process.

As the only oligonucleotide CMO that can deliver both the first µmols of pre-clinical material and bring a program through to commercialization, Avecia OliGrow creates value for its customers by building compound knowledge from the very start, avoiding future surprises and costly technical transfers and process changes.

Dr. Marc Lemaitre, Avecia’s VP for New Businesses and Services, says the company is very proud to bring this small scale service under the same roof as the large scale, clinical productions. “Previous options to bridge the gap between pure research and clinical production in the oligo space were largely accomplished through collaborations and partnerships between multiple companies. But now are pleased to offer OliGrow as a unique, one- stop option for oligonucleotide developers.”

ABOUT NITTO DENKO Avecia Inc.

NITTO DENKO Avecia, Inc. is a drug development and manufacturing services company located in Milford, MA, and is a part of Nitto Denko Corporation, Japan’s leading diversified materials manufacturer. Avecia is a recognized leader process development, manufacture, and related services for DNA and RNA-based therapeutics. All services are offered, from preclinical testing to post-commercial launch of innovative oligonucleotide-based therapeutics. To see what Avecia can do for your business, visit http://www.avecia.com

Read the full story at http://www.prweb.com/releases/2013/5/prweb10715509.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research
2. Montclair Breast Center introduces 3D Mammography.
3. Adult Acne Treatment, Probiotic Action Introduces their Antibiotic-Free Acne Treatment
4. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
5. Diagenode Introduces Innovative Bioruptor® Pico for Micro-Volume Chromatin and DNA Shearing
6. Texas Fertility Center Introduces Oncofertility Education Program for Physicians and Patients
7. Finesse Solutions Introduces SmartParts for Intelligent Universal Controllers
8. Cearna Introduces Product Designed to Reduce Patient’s Recovery Time From Facial Plastic Surgery
9. Rigaku Introduces New Instruments at Pittcon 2013
10. GIN Introduces Advanced Robotics and Dispensing Technology at BVS La Jolla Biotech Day
11. FMC BioPolymer Introduces Its New Portfolio of Nature-Based Nutritional Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
Breaking Biology Technology:
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):